Absci Corporation ABSI Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| R&D by Product | ||||||
| Drug creation program and platform | $22.44M+32.9% | $20.35M+23.2% | $19.83M+31.6% | $18.31M+27.6% | $16.88M+21.3% | |
| External preclinical and clinical development | $24.01M+100% | $22.4M+140% | $15.82M+205% | $15.06M+548% | $11.99M+44,319% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Absci Corporation break its business down?
- Absci Corporation (ABSI) reports r&d by product across 2 parts — Drug creation program and platform and External preclinical and clinical development. Each is extracted from the segment footnotes and tracked over time.
- Where does Absci Corporation's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Absci Corporation's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
